asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»10.21518/akh2023-027asurgery-386Research ArticleФЛЕБОЛОГИЯPHLEBOLOGYФлебопатии: от патогенеза к лечениюPhlebopathies: from pathogenesis to treatmenthttps://orcid.org/0000-0002-3940-0787БогачёвВ. Ю.BogachevV. Yu.

Богачёв Вадим Юрьевич, д.м.н., профессор, кафедра факультетской хирургии №2 лечебного факультета; научный руководитель 

117997, Москва, ул. Островитянова, д. 1;117447, Москва, ул. Дмитрия Ульянова, д. 31

Vadim Yu. Bogachev, Dr. Sci. (Med.), Professor of the Department of Faculty Surgery No. 2; Scientific Supervisor 

1, Ostrovityanov St., Moscow, 117997;31, Dmitry Ulyanov St., Moscow, 117447

vadim.bogachev63@gmail.comhttps://orcid.org/0000-0003-4488-9123БолдинБ. В.BoldinB. V.

Болдин Борис Валентинович, д.м.н., профессор, заведующий кафедрой факультетской хирургии №2 лечебного факультета 

117997, Москва, ул. Островитянова, д. 1

Boris V. Boldin, Dr. Sci. (Med.), Professor, Head of the Department of Faculty Surgery No. 2 

1, Ostrovityanov St., Moscow, 117997

bvb195411@mail.ruhttps://orcid.org/0000-0002-6262-4770ТуркинП. Ю.TurkinP. Yu.

Туркин Павел Юрьевич, к.м.н., доцент, кафедра факультетской хирургии 

117997, Москва, ул. Островитянова, д. 1

Pavel Yu. Turkin, Cand. Sci. (Med.), Associate Professor of the Department of Faculty Surgery No. 2 

1, Ostrovityanov St., Moscow, 117997

pavelturkin@gmail.comhttps://orcid.org/0000-0003-3811-5156ДженинаО. В.DzheninaO. V.

Дженина Ольга Вадимовна, к.м.н., врач-флеболог 

117447, Москва, ул. Дмитрия Ульянова, д. 31

Olga V. Dzhenina, Cand. Sci. (Med.), Phlebologist 

31, Dmitry Ulyanov St., Moscow, 117447

helgelman@mail.ruhttps://orcid.org/0000-0001-8982-7095АлуханянО. А.AlukhanyanO. A.

Алуханян Овик Арменович, д.м.н., профессор, кафедра кардиохирургии и кардиологии, Факультет повышения квалификации и профессиональной переподготовки специалистов 

350063, Краснодар, ул. Митрофана Седина, д. 4

Ovik A. Alukhanyan, Dr. Sci. (Med.), Professor, Department of Cardiology and Cardiac Surgery, Faculty of Advanced Training and Professional Retraining of Specialists 

4, Mitrofan Sedin St., Krasnodar, 350063

alovik@yandex.ruhttps://orcid.org/0000-0002-9483-246XБогачёваН. В.BogachevaN. V.

Богачёва Наталия Вадимовна, к.психол.н., доцент, заместитель директора по научной работе Института психолого-социальной работы 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Nataliya V. Bogacheva, Cand. Sci. (Psychol.), Associate Professor, Deputy Director for Science, Institute of Psychosocial Work 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

bogacheva.nataly@gmail.comРоссийский национальный исследовательский медицинский университет имени Н.И. Пирогова; Первый флебологический центрРоссияPirogov Russian National Research Medical University; First Phlebological CenterRussian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationПервый флебологический центрРоссияFirst Phlebological CenterRussian FederationКубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian FederationПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2023211120232024452Copyright © Богачёв В.Ю., Болдин Б.В., Туркин П.Ю., Дженина О.В., Алуханян О.А., Богачёва Н.В., 20232023Богачёв В.Ю., Болдин Б.В., Туркин П.Ю., Дженина О.В., Алуханян О.А., Богачёва Н.В.Bogachev V.Y., Boldin B.V., Turkin P.Y., Dzhenina O.V., Alukhanyan O.A., Bogacheva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/386

Введение. Частота встречаемости флебопатий варьирует от 15 до 31%, снижая качество жизни пациентов. Основным методом лечения флебопатий выступает флеботропная терапия. Цель. Оценить эффективность и безопасность микронизированной очищенной флавоноидной фракции (МОФФ) (Троксактив). Материалы и методы. В открытое наблюдательное исследование было включено 129 женщин от 18 до 45 лет (средний возраст 35,2 ± 4,1 года). Для исключения патологии магистральных вен нижних конечностей всем пациентам было выполнено ультразвуковое исследование, также фотоплетизмография с автоматическим измерением времени возвратного кровенаполнения и силы мышечно-венозной помпы голени. Все пациенты были разделены на три группы: в первой группе был назначен только препарат МОФФ в суточной дозе 1000 мг, во второй – дополнением к МОФФ компрессионный трикотаж I класса, в третьей – курс психотерапии и рекомендации по модификации образа жизни, повышению физической активности и т. д. Результаты. На фоне проводимых лечебных мероприятий отмечена положительная динамика с уменьшением количества жалоб и их интенсивности. Позитивные изменения произошли в основном в группах пациентов, получавших флеботропную терапию и комбинированную – флеботропная/компрессионная терапия: количество пациентов с веноспецифическими симптомами сократилось более чем в два раза, в то время как на фоне психотерапии и модификации образа жизни 31 человек отметил сохранение жалоб на исходном уровне или их незначительное уменьшение. В группах специфической терапии отмечено значимое динамическое снижение чувства тяжести и боли в икрах, а также ночных судорог. Обсуждение. В представленном исследовании МОФФ/Троксактив™ был назначен в суточной дозе 1000 мг как в виде монотерапии, так и в сочетании с компрессией. В обеих этих группах зафиксировано значимое уменьшение частоты и выраженности веноспецифических симптомов и существенное повышение качества жизни пациентов. Улучшились упругоэластические свойства венозной стенки по результатам фотоплетизмографии. Все пациенты остались удовлетворены проведенным лечением. Выводы. МОФФ/Троксактив™ продемонстрировал высокую эффективность и безопасность при лечении пациентов с флебопатиями различного генеза. 

Introduction. The prevalence of phlebopathies varies from 15 to 31%. The QoL of patients with phlebopathies is impaired. Phlebotropic therapy is the main method for treating phlebopathies. Aim. Evaluation of the efficacy and safety of micronized purified flavonoid fraction (MPFF) (Troxaktiv). Materials and methods. A total of 129 females aged 18 to 45 years (average age of 35,2 ± 4,1 years) were included in the open observational study. To exclude pathology of the principal veins of the lower extremities, all patients underwent ultrasound examination, as well as photoplethysmography with automatic measurements of the venous refilling time and the power of the calf muscle-venous pump. All patients were divided into three groups: Group 1 received MPFF at a daily dose of 1000 mg only, Group 2 – class I compression hosiery in addition to MPFF, Group 3 – a course of psychotherapy and guidelines on lifestyle changes, augmentation of physical activity, etc.Results. Due to ongoing treatment measures, positive changes with decreased number of complaints and their intensity were observed. Positive changes occurred mainly in the groups of patients receiving phlebotropic therapy and combined phlebotropic/compression therapy: the number of patients with vein-specific symptoms decreased by more than half, while 31 patients reported the persistence in complaints at baseline level or their slight decrease while taking psychotherapy course and lifestyle changes. The specific therapy groups reported a significant dynamic reduction in the feeling of heaviness and pain as well as night cramps in the calves. Discussion. In the presented study, the patients were prescribed MPFF/Troxaktiv™ at a daily dose of 1000 mg, both as monotherapy and in combination with compression. A significant decrease in the frequency and severity of vein-specific symptoms and a significant increase in the patients’ quality of life was recorded in both of these groups. Photoplethysmography results showed an improvement in elastic rebound properties of the venous wall. All patients were satisfied with the treatment. Conclusion. MPFF/Troxaktiv™ has demonstrated high efficacy and safety in the treatment of patients with phlebopathies of various origins.

флебопатииМОФФхронические заболевания венсимптомытерапияфлеботропные препаратыphlebopathyMPFFchronic venous diseasessymptomstherapyphlebotropic drugsReferencesRabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Rabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. https://doi.org/10.1016/j.jvsv.2019.12.075.Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. https://doi.org/10.1016/j.jvsv.2019.12.075.Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. https://doi.org/10.1016/j.jvs.2008.09.014.Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. https://doi.org/10.1016/j.jvs.2008.09.014.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Guex JJ, Rabe E, Escotto SI, Escudero J-R, Scuderi A, Yuwono HS. The ‘‘C0s’’ patient: worldwide results from the Vein Consult Program. Phlebolymphology. 2012;19:182–192. Available at: https://www.phlebolymphology.org/the-c0s-patient-worldwide-results-from-thevein-consult-program.Guex JJ, Rabe E, Escotto SI, Escudero J-R, Scuderi A, Yuwono HS. The ‘‘C0s’’ patient: worldwide results from the Vein Consult Program. Phlebolymphology. 2012;19:182–192. Available at: https://www.phlebolymphology.org/the-c0s-patient-worldwide-results-from-thevein-consult-program.Andreozzi G, Signorelli S, Di Pino L, Garozzo S, Cacciaguerra G, Leone A, Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://pubmed.ncbi.nlm.nih.gov/11195857.Andreozzi G, Signorelli S, Di Pino L, Garozzo S, Cacciaguerra G, Leone A, Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://pubmed.ncbi.nlm.nih.gov/11195857.Serra R, Grande R, Butrico L, Fugetto F, De Franciscis S. Epidemiology, diagnosis and treatment of chronic venous disease: a systematic review. Chirurgia. 2016;29(2):34–45. Available at: https://www.minervamedica.it/en/journals/chirurgia/article.php?cod=R20Y2016N02A0034#.Serra R, Grande R, Butrico L, Fugetto F, De Franciscis S. Epidemiology, diagnosis and treatment of chronic venous disease: a systematic review. Chirurgia. 2016;29(2):34–45. Available at: https://www.minervamedica.it/en/journals/chirurgia/article.php?cod=R20Y2016N02A0034#.Serra R, Andreucci M, De Caridi G, Massara M, Mastroroberto P, de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.Serra R, Andreucci M, De Caridi G, Massara M, Mastroroberto P, de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(Suppl. 1):11–19. https://doi.org/10.1177/00033197050560i103.Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(Suppl. 1):11–19. https://doi.org/10.1177/00033197050560i103.Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19(2):e73–77. https://doi.org/10.1055/s-0031-1278374.Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19(2):e73–77. https://doi.org/10.1055/s-0031-1278374.Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P et al. Estrogen Receptors and Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2016;52(1):114–118. https://doi.org/10.1016/j.ejvs.2016.04.020.Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P et al. Estrogen Receptors and Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2016;52(1):114–118. https://doi.org/10.1016/j.ejvs.2016.04.020.Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–330. https://doi.org/10.1016/j.jvs.2007.04.030.Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–330. https://doi.org/10.1016/j.jvs.2007.04.030.Богачев ВЮ. Гормоноиндуцированная флебопатия. Новая проблема современной флебологии. Ангиология и сосудистая хирургия. 2002;(3):50–54. Режим доступа: https://www.angiolsurgery.org/magazine/2002/3/7.htm.Bogachev VYu. Hormone-induced phlebopathy. A new problem of modern phlebology. Angiology and Vascular Surgery. 2002;(3):50–54. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2002/3/7.htm.Цуканов ЮТ, Цуканов АЮ. Клиническая оценка тяжести флебопатии на основе детализации симптома тяжести. Ангиология и сосудистая хирургия. 2003;(1):67–70. Режим доступа: https://www.angiolsurgery.org/magazine/2003/1/8.htm.Tsoukanov YuT, Tsoukanov AYu. Clinical assessment of phlebopathy severity by specification ofleg heaviness symptom. Angiology and Vascular Surgery. 2003;(1):67–70. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2003/1/8.htm.Цуканов ЮТ, Цуканов АЮ, Баженов ВН. Влияние оральных контрацептивов на магистральных диаметр вен нижних конечностей в ортостазе и их коррекция. Ангиология и сосудистая хирургия. 2008;(1):75–77. Режим доступа: https://www.angiolsurgery.org/magazine/2008/1/10.htm.Tsukanov YuT, Tsukanov AYu, Bazhenov VN. The effect of oral contraceptives on the orthostatic diameter of lower limb major veins and its correction. Angiology and Vascular Surgery. 2008;(1):75–77. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2008/1/10.htm.Цуканов ЮТ, Цуканов АЮ, Баженов ВН, Корниенко ИФ, Василевич ВВ. Медикаментозная коррекция негативных флеботропных эффектов гормонозаместительной терапии у женщин. Ангиология и сосудистая хирургия. 2009;(3):87–91. Режим доступа: https://www.angiolsurgery.org/magazine/2009/3/13.htm.Tsukanov YuT, Tsukanov AYu, Bazhenov VN, Kornienko IF, Vasilevich VV. Drug-mediated correction of negative phlebotropic effects of hormone replacement therapy in women. Angiology and Vascular Surgery. 2009;(3):87–91. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2009/3/13.htm.Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020;196:143–151. https://doi.org/10.1016/j.thromres.2020.08.039.Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020;196:143–151. https://doi.org/10.1016/j.thromres.2020.08.039.Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014.Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014.Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947. https://doi.org/10.1016/j.autrev.2021.102947.Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947. https://doi.org/10.1016/j.autrev.2021.102947.Богачев ВЮ, Болдин БВ, Туркин ПЮ, Дженина ОВ. COVID-19-ассоциированная флебопатия как актуальная проблема современной флебологии. Амбулаторная хирургия. 2022;19(2):13–20. https://doi.org/10.21518/1995-1477-2022-19-2.Bogachev VYu, Boldin BV, Turkin PYu, Dzhenina OV. COVID-19-associated phlebopathy as a current problem of modern phlebology. Ambulatornaya Khirurgiya. 2022;19(2):13–20. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-2.Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41(1):117–125. https://doi.org/10.1016/j.ejvs.2010.09.025.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41(1):117–125. https://doi.org/10.1016/j.ejvs.2010.09.025.Rabe E, Agus G, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://pubmed.ncbi.nlm.nih.gov/25972136.Rabe E, Agus G, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://pubmed.ncbi.nlm.nih.gov/25972136.Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392-9590.20.04388-6.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392-9590.20.04388-6.Мазайшвили КВ, Киян КА, Хлевтова ТВ, Цыплящук АВ, Суханов АВ, Ангелова ВА, Семкин ВД. Пациенты с С0S и C1S на амбулаторном приеме: следует ли думать о флебопатии? Флебология. 2016;(3):137–140. https://doi.org/10.17116/flebo2016103137-140.Mazayshvili KV, Kian RA, Khlevtova TV, Tsypliashuk AV, Suhanov AV, Angelova VA, Semkin VD. The Patient with C0S and C1S: Should a Phlebopathy Be Considered? Phlebology. 2016;(3):137–140. (In Russ.) https://doi.org/10.17116/flebo2016103137-140.Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29(9):580–586. https://doi.org/10.1177/0268355513515859.Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29(9):580–586. https://doi.org/10.1177/0268355513515859.Wrona M, Jöckel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013.Wrona M, Jöckel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013.Балахонова ТВ, Ершова АИ, Ежов МВ, Барбараш ОЛ, Берштейн ЛЛ, Богачев ВЮ и др. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. https://doi.org/10.15829/1728-8800-2022-3333.Balakhonova TV, Ershova AI, Ezhov MV, Barbarash OL, Bershtein LL, Bogachev VYu et al. Focused vascular ultrasound. Consensus of Russian experts. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(7):3333.(In Russ.) https://doi.org/10.15829/1728-8800-2022-3333.Шайдаков ЕВ, Санников АБ. Фотоплетизмографическая характеристика эффективности работы мышечно-венозной помпы голени в норме и у пациентов с хроническими заболеваниями вен различных клинических классов (по СЕАР). Амбулаторная хирургия. 2021;18(1):103–119. https://doi.org/10.21518/1995-1477-2021-18-1-103-119.Shaydakov EV, Sannikov AB. Photoplethysmographic characteristics of the efficiency of the calf muscle-venous pump in norm and in patients with cvd of various clinical classes according to CEAP. Ambulatornaya Khirurgiya. 2021;18(1):103–119. (In Russ.) https://doi.org/10.21518/1995-1477-2021-18-1-103-119.Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. https://doi.org/10.1136/jech.52.6.377.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. https://doi.org/10.1136/jech.52.6.377.Blazek C, Amsler F, Blaettler W, Keo HH, Baumgartner I, Willenberg T. Compression hosiery for occupational leg symptoms and leg volume: a randomized crossover trial in a cohort of hairdressers. Phlebology. 2013;28(5):239–247. https://doi.org/10.1258/phleb.2011.011108.Blazek C, Amsler F, Blaettler W, Keo HH, Baumgartner I, Willenberg T. Compression hosiery for occupational leg symptoms and leg volume: a randomized crossover trial in a cohort of hairdressers. Phlebology. 2013;28(5):239–247. https://doi.org/10.1258/phleb.2011.011108.Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000;51(1):31–37. https://doi.org/10.1177/000331970005100107.Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000;51(1):31–37. https://doi.org/10.1177/000331970005100107.Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53(3):245–256. https://doi.org/10.1177/000331970205300301.Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53(3):245–256. https://doi.org/10.1177/000331970205300301.Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229. https://doi.org/10.1002/14651858.CD003229.pub3.Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229. https://doi.org/10.1002/14651858.CD003229.pub3.Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.Tsukanov Y, Nicolaichuk A. Changes in clinical manifestations and biophysical properties of the great saphenous vein in transient premenstrual phlebopathy after 12 months’ treatment with micronized purified flavonoid fraction. Phlebolymphology. 2020;27(1):36–42. Available at: https://www.phlebolymphology.org/changes-in-clinical-manifestations-and-biophysical-properties-of-the-greatsaphenous-vein-in-transient-premenstrual-phlebopathy-after-12-months-treatment-with-micronized-purified-flavonoid-f/.Tsukanov Y, Nicolaichuk A. Changes in clinical manifestations and biophysical properties of the great saphenous vein in transient premenstrual phlebopathy after 12 months’ treatment with micronized purified flavonoid fraction. Phlebolymphology. 2020;27(1):36–42. Available at: https://www.phlebolymphology.org/changes-in-clinical-manifestations-and-biophysical-properties-of-the-greatsaphenous-vein-in-transient-premenstrual-phlebopathy-after-12-months-treatment-with-micronized-purified-flavonoid-f/.De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.

The authors declare that there are no conflicts of interest present.